HARVARD BIOSCIENCE INC

For the period ended Sep 30, 2025. Filed Nov 6, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 6, 2025

HBIO$9.26+1.9%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

(Unaudited, in thousands, except per share data)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2025	2024	2025	2024
Revenues	$20,591	$21,970	$62,815	$69,579
Cost of revenues	8,570	9,205	27,077	28,824
Gross profit	12,021	12,765	35,738	40,755
Sales and marketing expenses	4,613	5,518	14,123	16,817
General and administrative expenses	4,176	5,041	13,623	16,690
Research and development expenses	2,132	2,567	6,642	8,078
Amortization of acquired intangible assets	855	1,334	3,177	3,998
Goodwill impairment - Note 4	-	-	47,951	-
Other operating expenses - Note 1	48	179	512	1,394
Total operating expenses	11,824	14,639	86,028	46,977
Operating income (loss)	197	(1,874)	(50,290)	(6,222)
Other expense:
Interest expense	(966)	(856)	(2,559)	(2,356)
Loss on pension settlement	-	(1,243)		(1,243)
Loss on equity securities - Note 6	-	-	-	(1,593)
Other expense, net	(365)	(518)	(1,333)	(841)
Total other expense	(1,331)	(2,617)	(3,892)	(6,033)
Loss before income taxes	(1,134)	(4,491)	(54,182)	(12,255)
Income tax expense (benefit)	97	311	(329)	168
Net loss	$(1,231)	$(4,802)	$(53,853)	$(12,423)
Loss per share:
Basic and diluted loss per share	$(0.03)	$(0.11)	$(1.22)	$(0.29)
Weighted-average common shares:
Basic and diluted	44,556	43,614	44,320	43,499

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.